|
Printable version |
From: | "david.gibson" <david.gibson@k.co.nz> |
Date: | Fri, 27 Feb 2004 12:53:20 +1300 |
Cris,
I know
a bit about Genesis:
* a research based Biotech company - does
fundamental research and patents the results
* two
basic divisions - plant sciences and human health
*
recent setback with PVAC eczema phase II trials declared a
failure
*
WRI.NZX a significant investor - mainly interested in the plant
sciences/forestry side of the buisiness (could have even forced the recent
formal split of the company into the two divisions pending some future
separation).
The
company is best judged on its patent rate (reasonably high - see the web
site)
Valuation is difficult - share price is close to
current cash reserves
Jim
Watson is very highly regarded internationally as a
researcher
Investment in GEN.NZX should be considered highly
speculative.
However, there are many positive
points:
*
excellent people are involved in the company
*
patent rate is very high - share price values existing patents at practically
nothing
Some
concerns:
* cash
burn rate - the cash will eventually run out - it is not clear how
forward company momentum will be funded
*
commercialisation - big question about exactly how the existing and future
IP will be turned into cash
Disclosure: Hold GEN.NZX
/dbg
|
References
|